Drug manufacturer Merck misrepresented the efficacy of its mumps vaccine for years, "Overfilling" the vaccine with live mumps virus to meet efficacy targets despite the lack of safety testing - and the practice may be continuing today.
According to Hooker, the Merck measles, mumps rubella vaccine, MMR II - the only mumps vaccine licensed in the U.S. and listed on the childhood vaccine schedule for 12- to 18-month-olds - may contain up to 4 times the approved concentration of live mumps virus.
In this week's interview, Hooker emphasized that vaccine dosages with a higher concentration of live mumps virus were never tested for safety or efficacy.
Hooker explained that guidelines for the amount of live virus in the MMR II vaccine were last changed in 1999, "As a result of an FDA action that showed that the mumps portion of the vaccine was losing potency over its sort of two-year [shelf life] before the vaccine expired."
"The mumps portion of the vaccine lost its potency to an ineffective and an unacceptable endpoint, and the FDA notified Merck of this in 1998," Hooker said.
"In order to achieve immunity, according to the FDA, you only need 20,000 virus particles. So, looking at that, Merck is overfilling the vaccine, and it can be as high as 30 times what is required."
"The only way the FDA found out was when these court documents actually surfaced, because the only thing Merck directly told the FDA was the concentration of mumps virus [was] 160,000 virus particles," Hooker said.
https://childrenshealthdefense.org/defender/merck-mmr-vaccine-brian-hooker-defender-podcast/
No comments:
Post a Comment